Entering text into the input field will update the search result below

Basilea Pharmaceutica's (BPMUF) CEO Ronald Scott on Full Year 2017 Results - Earnings Call Transcript

Mar. 01, 2018 1:14 AM ETBasilea Pharmaceutica AG (BPMUF)
SA Transcripts profile picture
SA Transcripts

Basilea Pharmaceutica AG (OTC:BPMUF) Full Year 2017 Earnings Conference Call February 27, 2018 10:00 AM ET


Ronald Scott - Chief Executive Officer

Marc Engelhardt - Chief Medical Officer

David Veitch - Chief Commercial Officer and Chief Executive Officer-designate

Donato Spota - Chief Financial Officer


Bob Pooler - ValuationLAB

Bruno Bulic - Baader-Helvea


Ladies and gentlemen, good morning or afternoon. Welcome to the Basilea Pharmaceutical’s Conference Call on Full Year Results 2017. I’m Alister, the Chorus Call Operator. The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Mr. Ronald Scott, Chief Executive Officer. Please go ahead, sir.

Ronald Scott

Thank you. Hello. This is Ron Scott, CEO of Basilea, and I welcome you to our 2017 full results conference call. To update you on our progress, upcoming milestones, and guidance for 2018, to be followed by questions and answers session.

Joining me on this conference call are Marc Engelhardt, our Chief Medical Officer; David Veitch, our Chief Commercial Officer and our CEO-designate; and Donato Spota, our Chief Financial Officer.

I would also like to mention that this call contains forward-looking statements. For those on the call who are not familiar with Basilea we are one of the few companies, focused on new for medicines to overcome resistance in the areas of infectious diseases and oncology, our two strategic pillars in the hospital sector.

Basilea has a proven track record at up-bringing drugs from research into clinical development and onto the market. We have brought two anti-infective drugs from research to the market, our antifungal Cresemba, and Zevtera, our broad-spectrum antibiotic also covering MRSA.

2017 was a good year for us. We were able to finalize transactions to maximize the value of both our commercial stage drugs. This morning we

Recommended For You


To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!


SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on BPMUF

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.